vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v13i6.1206vsp-106Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSПРИМЕНЕНИЕ ЭТАНЕРЦЕПТА У ПАЦИЕНТА С ОЛИГОАРТИКУЛЯРНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМUSE OF ETANERCEPT IN PATIENTS WITH OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITISБзароваТ. М.BzarovaТ. М.neonatepearl@yandex.ruАлексееваЕ. И.AlekseevaYe. I.

Алексеева Екатерина Иосифовна, доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центра здоровья детей, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова

alekatya@yandex.ruЛомакинаО. Л.LomakinaО. L.neonatepearl@yandex.ruИсаеваК. Б.IsaevaK. B.neonatepearl@yandex.ruВалиеваС. И.ValievaS. I.neonatepearl@yandex.ruДенисоваР. В.DenisovaR. V.neonatepearl@yandex.ruСлепцоваТ. В.SleptsovaТ. V.neonatepearl@yandex.ruНаучный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Centre of Children Health, MoscowRussian FederationНаучный центр здоровья детей, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, Moscow; Sechenov First Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей, МоскваРоссияScientific Centre of Children Health, MoscowRussian Federation201410122014136Вопросы современной педиатрии7277Copyright © Бзарова Т.М., Алексеева Е.И., Ломакина О.Л., Исаева К.Б., Валиева С.И., Денисова Р.В., Слепцова Т.В., 20142014Бзарова Т.М., Алексеева Е.И., Ломакина О.Л., Исаева К.Б., Валиева С.И., Денисова Р.В., Слепцова Т.В.Bzarova Т.М., Alekseeva Y.I., Lomakina О.L., Isaeva K.B., Valieva S.I., Denisova R.V., Sleptsova Т.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/106детиэтанерцептсуставной синдромолигоартикулярный ЮИАchildrenetanerceptarticular syndromeoligoarticular JIAReferencesLandells I., MacCallum C., Khraishi M. The role of the derma tologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett. 2008; 13 (4): 4–7.Landells I., MacCallum C., Khraishi M. The role of the derma tologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett. 2008; 13 (4): 4–7.Brewer E.J. Jr, Bass J., Baum J. Current proposed revision of JRA criteria. Arthritis Rheum. 1977; 20 (Suppl.): 195.Brewer E.J. Jr, Bass J., Baum J. Current proposed revision of JRA criteria. Arthritis Rheum. 1977; 20 (Suppl.): 195.Szer I. S., Kimura Y., Malleson P. N., Southwood T. R. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford University Press. 2006. 456 p.Szer I. S., Kimura Y., Malleson P. N., Southwood T. R. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford University Press. 2006. 456 p.Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007. 360 с.Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди. 2007. 360 с.Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th edn. Philadelphia: Saunders Elsevier. 2010. 794 p.Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th edn. Philadelphia: Saunders Elsevier. 2010. 794 p.Lee D. M., Weinblatt M. E. Rheumatoid arthritis. Lanсet. 2001; 358: 903–911.Lee D. M., Weinblatt M. E. Rheumatoid arthritis. Lanсet. 2001; 358: 903–911.Karateev D. E. Modern approach to the problem of rapidly rheumatoid arthritis. Current rheumatology. 2010; 2: 37–42.Karateev D. E. Modern approach to the problem of rapidly rheumatoid arthritis. Current rheumatology. 2010; 2: 37–42.Sigidin Ya. A., Lukina G. V. Biologicheskaya terapiya v revmatologii. 2-e izd., dop. [Biological Therapy in Rheumatology. 2nd edn, enlarged]. Moscow: Prakticheskaya Meditsina. 2009. 245 p.Sigidin Ya. A., Lukina G. V. Biologicheskaya terapiya v revmatologii. 2-e izd., dop. [Biological Therapy in Rheumatology. 2nd edn, enlarged]. Moscow: Prakticheskaya Meditsina. 2009. 245 p.Bergman M., Furfaro N. Individualizing therapy for rheumatoid arthritis: New strategies for maximizing treatment outcomes. 2010 PCE Updates in Rheumatology. 2010; 3 (2): 1–12.Bergman M., Furfaro N. Individualizing therapy for rheumatoid arthritis: New strategies for maximizing treatment outcomes. 2010 PCE Updates in Rheumatology. 2010; 3 (2): 1–12.Smolen J., Aletaha D., Bijlsma J. W. J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010; 69: 631–637.Smolen J., Aletaha D., Bijlsma J. W. J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010; 69: 631–637.Алексеева Е. И., Слепцова Т. В., Валиева С. И. Эффективность и безопасность инфликсимаба у больных ранним и поздним ювенильным ревматодиным артритом. Вопросы современной педиатрии. 2010; 9 (3): 30–42.Алексеева Е. И., Слепцова Т. В., Валиева С. И. Эффективность и безопасность инфликсимаба у больных ранним и поздним ювенильным ревматодиным артритом. Вопросы современной педиатрии. 2010; 9 (3): 30–42.Abe T., Takeuchi T., Miyasaka N. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 2006; 33 (1): 37–43.Abe T., Takeuchi T., Miyasaka N. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 2006; 33 (1): 37–43.Van der Laken C. J., Voskuyl A. E., Roos J. C. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann. Rheum. 2007; 66: 253–256.Van der Laken C. J., Voskuyl A. E., Roos J. C. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann. Rheum. 2007; 66: 253–256.Bukhari M. A., Wiles N. J., Lunt M. et al. Influence of diseasemodifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 2003; 48: 46–53.Bukhari M. A., Wiles N. J., Lunt M. et al. Influence of diseasemodifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 2003; 48: 46–53.Алексеева Е. И., Григорьева А. А., Денисова Р. В. Причины развития резистентности к ингибиторам ФНО a и пути ее преодоления. Вопросы современной педиатрии. 2009; 8 (6): 42–47.Алексеева Е. И., Григорьева А. А., Денисова Р. В. Причины развития резистентности к ингибиторам ФНО a и пути ее преодоления. Вопросы современной педиатрии. 2009; 8 (6): 42–47.Алексеева Е. И., Лисицын А. О., Карагулян Н. А. Адалимумаб: новые возможности лечения ювенильных артритов. Вопросы современной педиатрии. 2009; 8 (3): 88–94.Алексеева Е. И., Лисицын А. О., Карагулян Н. А. Адалимумаб: новые возможности лечения ювенильных артритов. Вопросы современной педиатрии. 2009; 8 (3): 88–94.Lovell D. J. еt al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000; 342 (11): 763–769.Lovell D. J. еt al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000; 342 (11): 763–769.Papsdorf V., Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011; 50: 214–21.Papsdorf V., Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011; 50: 214–21.Otten M. H., Prince F. H., Armbrust W. et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA (Multicenter Study Research Support, Non-U. S. Gov’t). 2011; 306: 2340–2347.Otten M. H., Prince F. H., Armbrust W. et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA (Multicenter Study Research Support, Non-U. S. Gov’t). 2011; 306: 2340–2347.Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.Lamot L., Bukovac L. T., Vidovic M. et al. The ‘head-to-head’ comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2011; 29: 131–139.Lamot L., Bukovac L. T., Vidovic M. et al. The ‘head-to-head’ comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2011; 29: 131–139.Horneff G., Ruperto N., Burgos-Vargas R. et al. Effectiveness and safety of etanercept in paediatric subjects with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: the clipper study. Ann. Rheum. Dis. 2012; 71 (Suppl.): 424.Horneff G., Ruperto N., Burgos-Vargas R. et al. Effectiveness and safety of etanercept in paediatric subjects with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: the clipper study. Ann. Rheum. Dis. 2012; 71 (Suppl.): 424.Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of Juvenile Idiopathic Arthritis (JIA). Ann. Rheum. Dis. 2004; 63: 1638–1644.Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of Juvenile Idiopathic Arthritis (JIA). Ann. Rheum. Dis. 2004; 63: 1638–1644.Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with Juvenile Idiopathic Arthritis (JIA). Preliminary data from the German JIA registry. Ann. Rheum. Dis. 2009; 68 (4): 519–525.Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with Juvenile Idiopathic Arthritis (JIA). Preliminary data from the German JIA registry. Ann. Rheum. Dis. 2009; 68 (4): 519–525.Tanjala P., Vahasalo P., Honkanen V. et al. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2009; 68: 552–557.Tanjala P., Vahasalo P., Honkanen V. et al. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann. Rheum. Dis. 2009; 68: 552–557.Simonini G., Katie D., Cimaz R., Macfarlane G. J., Jones G. T. Does switching anti-TNF a biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach. Semin. Arthritis Rheum. 2014; 44.Simonini G., Katie D., Cimaz R., Macfarlane G. J., Jones G. T. Does switching anti-TNF a biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach. Semin. Arthritis Rheum. 2014; 44.

The authors declare that there are no conflicts of interest present.